← Leaderboards
Brian William Leblanc
Miriam Hospital
$886,579
Attributed
$886,579
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $322.2K · FY2020–22$500K$375K$250K$125K$0
'20
'21
'22
Funding mix
By agency
NIH$886,579 · 1
By mechanism
P20$886,579 · 1
Top collaborators
No co-investigators on record.
Most similar at Miriam Hospital
Same institution · by research overlap
- Josiah D Rich$21,388,960
- Philip Andrew Chan$10,525,667
- Curt G Beckwith$10,928,984
- Susan Cu-Uvin$17,969,413
- Timothy P Flanigan$23,302,591
Others in their field
Other Emerging Leaders on “Antibiotics”
- Urs Ochsner · Crestone, Inc.$36,950,837
- Ryan Cirz · Revagenix, Inc.$35,410,554
- Daniel Pevear · Venatorx Pharmaceuticals, Inc.$24,789,028
- Bruce Blough · Research Triangle Institute$19,637,160
- Thomas Dick · Rbhs-New Jersey Medical School$15,241,285
- Steven Armen Boyd · Venatorx Pharmaceuticals, Inc.$13,685,544
Research focus
AntibioticsAntimicrobial DrugAntimicrobial ResistanceBacterial Antibiotic ResistanceBiomedical ResearchBiotechnologyCandida AlbicansCareerCareer DevelopmentCenters Of Research ExcellenceCessation Of LifeChemotherapy-Oncologic ProcedureClinical MedicineClinical PracticeCommunicable DiseasesCommunitiesCore FacilityCostDedicationsDesignDisciplineDrug DiscoveryDrug ResistanceAntibiotic Resistance
Grant awards (3)
Neutrophil Integrins in Defense against Drug-Resistant C. albicans$322,198
P20 · FY2022 · GM · contact PI
Neutrophil Integrins in Defense against Drug-Resistant C. albicans$320,118
P20 · FY2021 · GM · contact PI
Neutrophil Integrins in Defense against Drug-Resistant C. albicans$244,263
P20 · FY2020 · GM · contact PI